Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma
Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma
复制标题
DOI：
10.1111/j.1872-034x.2008.00387.x
复制
发表时间：
2008-11-01
影响因子：
4.2
通讯作者：
Shimosegawa, Tooru
中科院分区：
文献类型：
--
作者：
Matsuda, Yasunori;Yamagiwa, Yoko;Shimosegawa, Tooru
目的：Galectins是一种多功能凝集素，与糖蛋白的β-半乳糖苷结合，影响多种生理和病理生理过程，如发育、炎症和肿瘤生长。在肝细胞癌中，Galectin-1、Galectin-3和Galectin-4的过度表达已被报道，尽管它们的功能和与肿瘤进展的相关性尚不清楚。因此，我们的目的是评估Galectin-3在肝癌进展中的作用。方法：在根治性手术中获取标本，用于Galectin-3的免疫组织化学分析(n=52)，并对其与临床特征和患者预后的相关性进行统计学评估。结果：52例肝肿瘤中有34例(65%)Galectin-3表达，且与肿瘤分化程度、血管侵犯程度有关。Kaplan-Meier的分析表明，Galectin-3表达的患者在早期倾向于复发，总体生存较差。尤其是核Galectin-3表达水平越高，预后越差，在影响总体生存的多因素分析中是独立的。肝细胞癌患者血清Galectin-3水平明显高于慢性肝病患者。Galectin-3的敏感性和特异性与甲胎蛋白、维生素K缺失或拮抗剂II相当，联合检测可提高诊断效率。结论：Galectin-3的表达参与了肝癌的发生发展，并与预后有关。我们的观察结果提示Galectin-3可能成为一种新的肿瘤标志物和治疗靶点。
Aims:Galectins are multifunctional lectins binding to the beta-galactoside of glycoproteins that affect diverse physiological and pathophysiological processes such as development, inflammation and tumor growth. In hepatocellular carcinoma (HCC), the over-expression of galectin-1, 3, and 4 has been reported, although their function and correlation with tumor progression remain unknown. Thus, we aimed to assess the role of galectin-3 during HCC progression.Methods: Specimens were obtained during curative operations and used for immunohistochemical analysis of galectin-3 (n = 52), and statistically assessed for correlations with the clinical profiles and the prognoses of the patients. The serum galectin-3 levels from the patients with liver diseases including HCC were assessed by ELISA.Results: In total, galectin-3 expression was found in 34 of 52 tumors (65%) and was statistically correlated with histological differentiation and vascular invasion. Kaplan-Meier's analysis showed that patients with galectin-3 expression tended to relapse in the earlier phase and had worse overall survival. In particular, a higher expression rate of nuclear galectin-3 showed a markedly worse prognosis, and it was independent in the multivariate analysis for overall survival. Serum galectin-3 levels were significantly increased in HCC compared with chronic liver disease. The sensitivity and specificity of galectin-3 were equivalent to alpha-fetoprotein and Vitamin K absence or antagonist II, and the combination of HCC biomarkers with galectin-3 improved the diagnostic performance.Conclusions: Galectin-3 expression was involved in the tumor progression and related to the prognosis of HCC. Our observations suggested that galectin-3 could be a novel tumor marker and therapeutic target.